Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Daiichi Sankyo And AstraZeneca's ENHERTU Receives Breakthrough Therapy Designation In The U.S. For Specific Patients With HER2 Low Or Ultralow Metastatic Breast Cancer

Author: Benzinga Newsdesk | August 19, 2024 02:29am

Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results
Eleventh Breakthrough Therapy Designation granted by FDA across Daiichi Sankyo's oncology pipeline

Posted In: AZN DSNKY